期刊文献+

非酒精性脂肪性肝病治疗新策略

原文传递
导出
摘要 非酒精性脂肪性肝病(Nonalcoholic fatty liver disease,NAFLD)患者的治疗方法最常见的是改变生活方式,包括增强体育锻炼和饮食干预”。。。其他治疗包括抗炎药、抗氧化剂、降脂药剂、胰岛素增敏剂,以及补充维生素等”。近年来发现肠道菌群紊乱在NAFLD发病中发挥重要作用,调节肠道菌群成为治疗NAFLD新策略。抗生素、益生元、益生菌和粪便微菌群移植,调整肠道菌群代谢产物等基于菌群失调的治疗方法可能是未来治疗NAFLD的重要措施。
作者 肖丽 杨玲
出处 《医学新知》 CAS 2017年第2期113-115,共3页 New Medicine
基金 国家自然科学基金资助(NO.81370550,81570530)
  • 相关文献

参考文献2

二级参考文献36

  • 1Vettickattuparambil George Giby,Thekkuttuparambil Ananthanarayanan Ajith.Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease[J].World Journal of Hepatology,2014,6(8):570-579. 被引量:30
  • 2Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of nonalcoholicfatty liver disease: practice Guideline by the AmericanAssociation for the Study of Liver Diseases, American Collegeof Gastroenterology, and the American GastroenterologicalAssociation. Hepatology 2012; 55: 2005-2023 [PMID: 22488764DOI: 10.1002/hep.25762].
  • 3Rozman D. From nonalcoholic Fatty liver disease to hepatocellularcarcinoma: a systems understanding. Dig Dis Sci 2014; 59: 238-241[PMID: 24385011 DOI: 10.1007/s10620-013-2998-x].
  • 4Arendt BM, Allard JP. Effect of atorvastatin, vitamin E and C onnonalcoholic fatty liver disease: is the combination required- Am JGastroenterol 2011; 106: 78-80 [PMID: 21212755 DOI: 10.1038/ajg.2010.310].
  • 5Pamuk GE, Sonsuz A. N-acetylcysteine in the treatment ofnonalcoholic steatohepatitis. J Gastroenterol Hepatol 2003; 18:1220-1221 [DOI: 10.1046/j.1440-1746.2003.03156.x].
  • 6Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-BladouC, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spénard J. A randomizedcontrolled trial of high-dose ursodesoxycholic acid for nonalcoholicsteatohepatitis. J Hepatol 2011; 54: 1011-1019 [PMID: 21145828DOI: 10.1016/j.jhep.2010.08.030].
  • 7Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM,Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, BruntEM, McCullough AJ, Bass NM, Diehl AM, Unalp-Arida A, ChalasaniN. Relationship between adipose tissue insulin resistance and liverhistology in nonalcoholic steatohepatitis: a pioglitazone versusvitamin E versus placebo for the treatment of nondiabetic patients withnonalcoholic steatohepatitis trial follow-up study. Hepatology 2012;56: 1311-1318 [PMID: 22532269 DOI: 10.1002/hep.25805].
  • 8Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D.Relation between augmentation index and adiponectin during oneyearmetformin treatment for nonalcoholic steatohepatosis: effectsbeyond glucose lowering- Cardiovasc Diabetol 2012; 11: 61 [PMID:22676459 DOI: 10.1186/1475-2840-11-61].
  • 9Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCulloughAJ, Hazen SL, Feldstein AE. Pentoxifylline decreases oxidizedlipid products in nonalcoholic steatohepatitis: new evidence on thepotential therapeutic mechanism. Hepatology 2012; 56: 1291-1299[PMID: 22505276 DOI: 10.1002/hep.25778].
  • 10Day CP. Pathogenesis of steatohepatitis. Best Pract Res ClinGastroenterol 2002; 16: 663-678 [PMID: 12406438 DOI: 10.1053/bega.2002.0333].

共引文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部